Understanding GLP‑1 Receptor Agonist Mechanisms: From Preclinical Fluorescent Assays to Drug Action

In the last decade, GLP-1 receptor agonists, also known as GLP-1RAs, have moved from being a promising therapeutic concept to one of the fastest-growing drug classes in metabolic disease. Understanding their mechanism of action provides a framework for optimizing efficacy, minimizing side effects, and expanding applications beyond diabetes to include other areas such as the treatment of obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), and even neurodegeneration. At the same time, the complexity of the GLP-1 receptor signaling pathway demands preclinical models that are both reliable and precise. This is where advanced fluorescent assays are redefining how receptor behavior, ligand interactions, and signaling bias can be studied, providing translational data that directly impacts the development of next-generation therapeutics.

What Are GLP-1 Receptor Agonists and How Do They Work?

GLP-1 receptor agonists are a type of drug that mimics the effects of the endogenous glucagon-like peptide-1 (GLP-1), a hormone released through the enzymatic breakdown of proglucagon in the intestinal mucosa, the pancreas, or some neurons. These compounds bind to the GLP-1 receptor, a G protein-coupled receptor (GPCR) expressed mainly in pancreatic β-cells, hypothalamic neurons, and peripheral tissues. Upon activation, the receptor triggers intracellular signaling cascades, mainly via cyclic adenosine monophosphate (cAMP) production and protein kinase A (PKA) activation. These events lead to:

• Glucose-dependent stimulation of insulin secretion.
• Suppression of glucagon release, ultimately lowering blood glucose levels.
• Delay in gastric emptying.
• Promotion of satiety through actions on the central nervous system, including GLP-1 receptors in the brain.

The mechanism of action of GLP-1 receptor agonists underlies their effectiveness in blood glucose control, with the added benefit of a low risk of hypoglycemia. Additionally, these drugs can protect β-cells from apoptosis and may stimulate their regeneration. Because of their diverse biological effects, these drugs hold promise for delivering therapeutic benefits in a wide range of human diseases.

Common GLP-1 Agonist Drugs and Their Clinical Applications

Since the approval of the first GLP-1 RA by the Food and Drug Administration (FDA) in 2005 (exenatide), several GLP-1 receptor agonist drugs have been widely used in clinical practice. The list includes medications with unique pharmacokinetic properties, such as: 

• Liraglutide
• Dulaglutide
• Semaglutide
• Dual and triple agonists, such as tirzepatide (GLP-1/GIP)
• Emerging triple-target compounds

Clinically, these drugs are primarily prescribed for the treatment of type 2 diabetes, but they also have additional benefits in obesity management, cardiovascular risk reduction, and, to some extent, fatty liver disease. Their broad metabolic effects make them valuable tools for tackling complex metabolic syndromes. However, like most therapies targeting metabolic pathways, they are not free of risks. The side effects of GLP-1 RAs can include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which are usually transient but may affect patient adherence, as well as rarer complications that require careful monitoring in clinical practice.

Challenges in Preclinical GLP-1 Research and the Role of Fluorescent Assays

Studying the interaction between ligands and the GLP-1 receptor requires robust preclinical methods that combine sensitivity with the capacity to resolve highly dynamic, subcellular processes. Standard binding and second-messenger assays often lack the temporal and spatial resolution needed for nuanced pharmacodynamic studies. 

This challenge has driven the adoption of advanced fluorescent assays, which have revolutionized pharmacological research. These tools enable real-time visualization of receptor binding and activation, trafficking, and ligand-receptor dynamics in living cells and tissues, dramatically improving the reliability and throughput of drug screening. For instance, LUXendins (such as LUXendin551, LUXendin645, or LUXendin762) are antagonistic red and far-red fluorescent probes that reveal GLP-1 receptor organization into membrane nanodomains and distinct cell subpopulations in pancreatic islets and brain. They allow super-resolution tracking of individual receptors and precise mapping of expression, overcoming antibody limitations.

Building on these tools, new dual agonist fluorescent probes such as daLUXendins enable the simultaneous investigation of GLP1R and GIPR (glucose-dependent insulinotropic polypeptide receptor), a critical advancement for studies on multi-agonist therapeutics in diabetes and obesity.

Figure 1. Labeling of live cells with LUXendin492, LUXendin551, and LUXendin615. SNAP-GLP1R:CHO-K1 cells were incubated with LUXendin492 (LUX492), LUXendin551 (LUX551), and LUXendin615 (LUX615) before orthogonal SNAP-labeling with either cell-impermeable SBG-TMR or SBG-SiR and confocal imaging (nuclei were stained using Hoechst33342) (scale bar = 10 μm) (n = three images from experiments performed in duplicate). Adapted from: Ast J, Novak AN et al. Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo. JACS Au. 2022 Apr 4;2(4):1007-1017.

GLP-1 Receptor Signaling Pathways and Implications for Drug Design

The GLP-1 receptor signaling pathway begins when a GLP-1 agonist binds to its GPCR, triggering multiple mechanisms:

• In pancreatic β-cells, the cAMP/PKA axis enhances insulin release. 
• In neurons, GLP-1 signaling modulates appetite and reward circuits, contributing to weight management. 
• Parallel pathways, including MAPK/ERK and PI3K/Akt, support cell survival and proliferation.

This diversity of signaling has opened the door to drug design strategies based on biased agonism. For example, compounds that preferentially activate G protein pathways may enhance metabolic benefits while reducing side effects. Others are engineered to cross the blood-brain barrier and directly engage GLP-1 receptors in the brain, amplifying appetite-suppressing effects.

For drug development, the GLP-1 receptor agonist structure should also be considered, since ligand orientation, peptide modifications, and half-life-extending features directly influence pharmacokinetics and receptor interactions. The structural design is tightly linked to the therapeutic profile, enabling the next generation of innovative GLP-1 RA drugs.

As research into GLP‑1 receptor agonists accelerates, leveraging cutting-edge fluorescent assay platforms is pivotal for producing robust, actionable pharmacological data. Celtarys supports drug discovery teams and academic labs by providing advanced fluorescent ligands, probes, and assay development services tailored for GPCR research, including GLP-1 receptor projects. These solutions enable greater precision, speed, and reliability in screening and mechanistic studies, driving innovation from bench to clinic. 

To learn how Celtarys can empower your next GLP‑1 drug discovery project, contact our scientific support team today!

References

Ast J, Arvaniti A, Fine NHF, Nasteska D, Ashford FB, Stamataki Z, Koszegi Z, Bacon A, Jones BJ, Lucey MA, Sasaki S, Brierley DI, Hastoy B, Tomas A, D’Agostino G, Reimann F, Lynn FC, Reissaus CA, Linnemann AK, D’Este E, Calebiro D, Trapp S, Johnsson K, Podewin T, Broichhagen J, Hodson DJ. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat Commun. 2020 Jan 24;11(1):467. doi: 10.1038/s41467-020-14309-w 

Ast J, Novak AN, Podewin T, Fine NHF, Jones B, Tomas A, Birke R, Roßmann K, Mathes B, Eichhorst J, Lehmann M, Linnemann AK, Hodson DJ, Broichhagen J. Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo. JACS Au. 2022 Apr 4;2(4):1007-1017. doi: 10.1021/jacsau.2c00130

de Bray A, Roberts AG, Armour S, Tong J, Huhn C, Gatin-Fraudet B, Roßmann K, Shilleh AH, Jiang W, Figueredo Burgos NS, Trott JPP, Viloria K, Nasteska D, Pearce A, Miyazaki S, Tomlinson JW, Owen DM, Nieves DJ, Ast J, Cyranka M, Epanchintsev A, Ämmälä C, Reimann F, Soykan T, Ladds G, Adriaenssens AE, Trapp S, Jones B, Broichhagen J, Hodson DJ. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain. Nat Metab. 2025 Aug;7(8):1536-1549. doi: 10.1038/s42255-025-01342-6 

Majellaro M, Bondar A. Editorial: Advanced biophysical and biochemical technologies to study GPCR signal transduction. Front Endocrinol (Lausanne). 2024 Jan 4;14:1354689. doi: 10.3389/fendo.2023.1354689 

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z